fda glp 1 Pharmacovigilance Assessment of Compounded GLP-1 Receptor Agonists: Insights From the Adverse Event Reporting System Compounded" GLP-1 drugs | Health
Description
Participants of the recent SURMOUNT-1 clinical trial saw weight loss of 15.0% for those on a 5 mg dose of Mounjaro 19.5% for those on a 10 mg dose, and 20.9% for those on a 15 mg dose after a 72-week period
2024 May 21:17474930241253988
A few limitations exist within this study
Whether a purchase is reimbursable depends on your account rules and supporting documentation
